drugset / Trial / NCT03833921

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

NCT03833921 ↗

Phase 2 Recruiting 130 enrolled Martha Mims
NaSingle-groupOpen-labelTreatment

Summary

The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.

Timeline

Start
2019-05-23
Primary completion
2028-11
Completion
2038-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Prednisone Other / unclassified 5 mg Oral